Back to search

Peptide record

TPDB03337

L6A Antibacterial Anticancer Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03337
L6A
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
KWKSFAKTFKSAKKTVLHTALKAISS
Physicochemical Analysis
C136H224N36O34
RNDCEQGMPY
K
2907.50
11.29
8
0
11
+7
2.68
-0.292
71.54
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
189.17
7
Residue Composition
number
4
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
2
L
7
K
0
M
2
F
0
P
4
S
3
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 4 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 2 K: 7 M: 0 F: 2 P: 0 S: 4 T: 3 W: 1 Y: 0 V: 1
Chemical Descriptors
26
C136H224N36O34
2907.50
11.29
+7
2.68
-0.292
Free
L
Linear
Free
Anticancer
PeptideV13K
Evidence Records 11 records
Evidence 1 Activity

Activity

IC50
IC50=53 µMo/L
Anticancer
53 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=58.7 µMo/L
Anticancer
58.7 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 3 Activity

Activity

IC50
IC50=62.3 µMo/L
Anticancer
62.3 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 4 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 5 Activity

Activity

IC50
IC50=>83.6 µMo/L
Anticancer
>83.6 µM

Target

Rhabdomyosarcoma Cancer
RD
Muscle

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 6 Activity

Activity

IC50
IC50=14 µMo/L
Anticancer
14 µM

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 7 Activity

Activity

IC50
IC50=62.5 µMo/L
Anticancer
62.5 µM

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 8 Activity

Activity

IC50
IC50=58.6 µMo/L
Anticancer
58.6 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
36-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 9 Activity

Activity

<5% Hemolysis
Toxicity
500 µM
Hemolytic Cytotoxic
<5% Hemolysis | 500 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Specificity and mechanism of action of alpha-helical membrane-active peptides interacting with model and biological membranes by single-molecule force spectroscopy. | Sci Rep | 2016
Evidence 10 Activity

Activity

50% Cell death
Toxicity
87.3 µM
Cytotoxic
50% Cell death | 87.3 | µM | target cell: Mouse fibroblasts 3T3-L1

Target

Mouse fibroblasts 3T3-L1

Source & Reference

NA
DBAASP
Specificity and mechanism of action of alpha-helical membrane-active peptides interacting with model and biological membranes by single-molecule force spectroscopy. | Sci Rep | 2016
Evidence 11 Activity

Activity

MHC
Toxicity
334.4 µm
Hemolytic Cytotoxic
Hemolytic_activity: Human red blood cells: MHC>334.4 µmol/L | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Mol Cancer Ther. 2011 Mar 10(3):416-26.